Selected Publications
Singh, Aditi P; Berman, Abigail T; Marmarelis, Melina E; Haas, Andrew R; Feigenberg, Steven J; Braun, Jennifer; Ciunci, Christine A; Bauml, Joshua M; Cohen, Roger B; Kucharczuk, John C; Shulman, Lawrence N; Langer, Corey J; Aggarwal, Charu.: Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract 16 (9): 579-586,2020.
Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, Yee SS, Christensen TE, LaRiviere MJ, Silva BA, Banks KC, Nagy RJ, Helman E, Berman AT, Ciunci CA, Singh AP, Wasser JS, Bauml JM, Langer CJ, Cohen RB, Carpenter EL.: Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Clin Cancer Res 26 (10): 2354-2361,2020.
Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT.: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC. Int J Radiat Oncol Biol Phys. 106 (2): 358-68,2020.
Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.: Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. : 2019.
Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 111 (5): 490-497,2019.
Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.: Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 5 (2): 173-180,2019.
Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.: Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 3 : 2019.
Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.: Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol : 2018.
Evans T, Ciunci C, Hertan L, Gomez D.: Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res. 6 (2): 119-130,2017.
Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106 : 1-7,2017.
Academic Contact Information
Abramson Cancer Center
Penn Presbyterian Medical Center
Pavilion for Advanced Care, 1st Floor
51 N 39th Street
Philadelphia,
PA
19104
Phone: 215-662-9801
Patient appointments: 800-789-7366